?
No comments here
Why not start the discussion?
There may be hundreds of biological, pharmaceutical, vaccine and device products in development at once in the event of a public health emergency. It will be important to prioritize development of the most promising products in consideration of the limitations of resources needed to test, review, manufacture and distribute them. Products with the following characteristics will be considered to have high potential:
They meet WHO Programmatic Suitability Mandatory and Critical Characteristics
They are manufactured using a platform that scores high on the Platform Readiness Dashboard
They are manufactured with a low cost of goods targeting less than $10/dose, if possible